Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 19/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 8/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22688715 | 1.00 | NTRK1 (0.40) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL29422685 | 0.93 | NTRK1 (0.42) | NTRK1NTRK3NTRK2JAK2 | |
| SCHEMBL29797171 | 0.89 | NTRK1 (0.42) | NTRK1NTRK3NTRK2 | |
| SCHEMBL22688882 | 0.88 | NTRK1 (0.42) | NTRK1NTRK3NTRK2 | |
| SCHEMBL22688879 | 0.88 | NTRK1 (0.42) | NTRK1NTRK3NTRK2 | |
| SCHEMBL29422676 | 0.87 | NTRK1 (0.40) | NTRK1NTRK3NTRK2 | |
| SCHEMBL29422764 | 0.86 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL22695326 | 0.86 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL29422547 | 0.86 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL22689129 | 0.86 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974434-B1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12410191-B2 | Macrolide derivatives, preparation method and application thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20220235070-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI ARYL PHARMTECH CO., LTD. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3974434-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020233645-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | 浙江海正药业股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233645-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | 浙江海正药业股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235070-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | ROS1, IRAK1, IRAK2 | NTRK1 51/4885NTRK3 71/4885NTRK2 336/4885 |
| US-12410191-B2 | Macrolide derivatives, preparation method and application thereof | ROS1, IRAK1, IRAK2 | NTRK1 51/4885NTRK3 71/4885NTRK2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.